Protalix Biotherapeutics, Inc. PLX 深 沪
等待开盘 10-14 09:30:00 美东时间
2.75
-0.030
-1.08%
华盛通- 最 高2.80
- 今 开2.80
- 成交量 96.78万股
- 最 低 2.735
- 昨 收 2.78
- 总市值 2.22亿
- 52周最高 3.19
- 市盈率 静 --
- 换手率 1.20%
- 52周最低 1.65
- 委 比 -13.29%
- 总股本 8057.16万
- 历史最高 77.00
- 量 比 1.05
- 振 幅 2.34%
- 历史最低 0.70
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Protalix BioTherapeutics (AMEX:PLX) with a Buy and maintains $12 price target.
09-09 22:47
普罗塔利斯生物制药 (PLX) 2026年第二季度业绩电话会议：Elfabrio驱动营收增长
受Elfabrio推动增长，Protalix BioTherapeutics 2026年第二季度营收增长26.8%至1990万美元，同时管理层重申了其全年业绩展望。
08-14 08:35
Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.12 by 58.33 percent. The company reported quarterly sales of $19.896 million which beat the analyst consensus estimate of $12.931 million by 53.86 percent. This is a 2...
08-12 18:51
Protalix BioTherapeutics Q2 Earnings Preview
Protalix BioTherapeutics (PLX) is scheduled to announce Q2 earnings results on Wednesday, August 12th, before market open. The consensus EPS estimate is -$0.01, and the consensus revenue estimate is $...
08-11 23:10
Protalix reaffirms $78M-$83M 2026 revenue outlook following $25M Elfabrio milestone
Earnings Call Insights: Protalix BioTherapeutics (PLX) Q1 2026 Management View “During the quarter, we received a $25 million milestone from Chiesi, following the European Commission approval of Elfab...
05-13 23:52
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Protalix BioTherapeutics Q1 EPS $0.05 Misses $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 16.67 percent. This is a 200 percent increase over losses of $(0.05) per share
05-13 19:02
Protalix BioTherapeutics give Q1 results
Protalix BioTherapeutics press release (PLX): Q1 GAAP EPS of $0.22 Revenue of $33.75M (+233.8% Y/Y) The Company reaffirms its previously stated 2026 revenue expectations: Total revenue in 2026 to ra...
05-13 18:53
